Literature DB >> 8814459

Effect of IL-10 on collagen-induced arthritis in mice.

Y Tanaka1, T Otsuka, T Hotokebuchi, H Miyahara, H Nakashima, S Kuga, Y Nemoto, H Niiro, Y Niho.   

Abstract

In the present study we investigated the effect of a potent anti-inflammatory cytokine, interleukin (IL)-10, on the development of collagen-induced arthritis (CIA) in mice. Each DBA1/J mouse was immunized with 200 micrograms of native collagen and followed by booster injections at 3 weeks. rmIL-10 was injected i.p. daily at a dose of 100 ng/mouse. Mice were divided into four groups according to the administration period of rmIL-10. As a result, a 48-day course of IL-10 treatment significantly suppressed the severity of arthritis. Among the 4 groups, the most pronounced suppression was observed in the group in which IL-10 was given from day 0 to 21. On the other hand, there were no significant differences in the serum IgG anti-type II collagen (CII) titers between the four groups. Moreover, the production of cytokines (IL-6 and tumor necrosis factor-alpha (TNF-alpha)) and other mediators (prostaglandin E2 (PGE2) and nitric oxide (NO)) by peritoneal macrophages seemed to show no clear correlation with the severity of arthritis in mice. These results raise the possibility that IL-10 might be a useful agent for suppressing the progression and the development of CIA in mice.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814459     DOI: 10.1007/bf02280992

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  30 in total

Review 1.  Rheumatoid arthritis. Pathophysiology and implications for therapy.

Authors:  E D Harris
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

2.  Tumour necrosis factor in synovial exudates.

Authors:  F S Di Giovine; G Nuki; G W Duff
Journal:  Ann Rheum Dis       Date:  1988-09       Impact factor: 19.103

3.  Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor.

Authors:  P F Piguet; G E Grau; C Vesin; H Loetscher; R Gentz; W Lesslauer
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

4.  The effect of an interleukin-1 receptor antagonist protein on type II collagen-induced arthritis and antigen-induced arthritis in mice.

Authors:  P H Wooley; J D Whalen; D L Chapman; A E Berger; K A Richard; D G Aspar; N D Staite
Journal:  Arthritis Rheum       Date:  1993-09

5.  Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes.

Authors:  F Rousset; E Garcia; T Defrance; C Péronne; N Vezzio; D H Hsu; R Kastelein; K W Moore; J Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

6.  Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.

Authors:  A P Cope; D Aderka; M Doherty; H Engelmann; D Gibbons; A C Jones; F M Brennan; R N Maini; D Wallach; M Feldmann
Journal:  Arthritis Rheum       Date:  1992-10

7.  Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha.

Authors:  C Haworth; F M Brennan; D Chantry; M Turner; R N Maini; M Feldmann
Journal:  Eur J Immunol       Date:  1991-10       Impact factor: 5.532

8.  IL-10 inhibits prostaglandin E2 production by lipopolysaccharide-stimulated monocytes.

Authors:  H Niiro; T Otsuka; S Kuga; Y Nemoto; M Abe; N Hara; T Nakano; T Ogo; Y Niho
Journal:  Int Immunol       Date:  1994-04       Impact factor: 4.823

9.  Murine type II collagen arthritis. Association of an acute-phase response with clinical course.

Authors:  M L Bliven; P H Wooley; M B Pepys; I G Otterness
Journal:  Arthritis Rheum       Date:  1986-09

10.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

Authors:  R de Waal Malefyt; J Haanen; H Spits; M G Roncarolo; A te Velde; C Figdor; K Johnson; R Kastelein; H Yssel; J E de Vries
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  19 in total

1.  Interleukin-10 ameliorates the outcome of Staphylococcus aureus arthritis by promoting bacterial clearance.

Authors:  I Gjertsson; O H Hultgren; A Tarkowski
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 2.  B-cell involvement in the pathogenesis of RA-is there a contribution of the sympathetic nervous system?

Authors:  Georg Pongratz; Rainer H Straub
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 3.  Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?

Authors:  R O Williams
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Cytokine therapy in rheumatoid arthritis.

Authors:  J Hermann; M Walmsley; F M Brennan
Journal:  Springer Semin Immunopathol       Date:  1998

Review 5.  Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.

Authors:  Shankar Subramanian Iyer; Gehong Cheng
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

6.  Intravenous tolerization with type II collagen induces interleukin-4-and interleukin-10-producing CD4+ T cells.

Authors:  M L Gumanovskaya; L K Myers; E F Rosloniec; J M Stuart; A H Kang
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

7.  Regulatory role of interleukin-10 in experimental group B streptococcal arthritis.

Authors:  Manuela Puliti; Christina Von Hunolstein; Claudie Verwaerde; Francesco Bistoni; Graziella Orefici; Luciana Tissi
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

8.  Adenoviral delivery of interleukin-10 fails to attenuate experimental Lyme disease.

Authors:  Charles R Brown; Annie Y-C Lai; Steven T Callen; Victoria A Blaho; Jennifer M Hughes; William J Mitchell
Journal:  Infect Immun       Date:  2008-09-29       Impact factor: 3.441

9.  Release of heat shock protein 70 and the effects of extracellular heat shock protein 70 on the production of IL-10 in fibroblast-like synoviocytes.

Authors:  Xinjing Luo; Xiaoxia Zuo; Bing Zhang; Lan Song; Xing Wei; Yaou Zhou; Xianzhong Xiao
Journal:  Cell Stress Chaperones       Date:  2008-04-08       Impact factor: 3.667

10.  Opposing roles for heat and heat shock proteins in macrophage functions during inflammation: a function of cell activation state?

Authors:  Chen-Ting Lee; Elizabeth A Repasky
Journal:  Front Immunol       Date:  2012-06-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.